Last edition
News about "Injectable Therapies"
Mankind Pharma In-Licenses Two Insulin Analogues from China for Indian Market
Mankind Pharma has signed an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical for Insulin Degludec and Insulin Degludec plus Aspart combination in India, strengthening its injectable diabetes portfolio.
Injectable Therapies | 20/08/2026 | By News Bureau
Neuraxpharm and Pharmathen to Co-Develop Long-Acting Injectable Therapies
Under this agreement, Neuraxpharm will have exclusive rights to commercialise these therapies in Europe, and in countries outside of Europe where the group has a direct presence, while Pharmathen will have exclusive rights for North America and all other countries not covered by Neuraxpharm.
Injectable Therapies | 23/12/2024 | By Aishwarya | 563
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy